{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:19:55Z","timestamp":1778498395636,"version":"3.51.4"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Rigid prespecification can be impractical for noninterventional studies using secondary datasets, where data-driven flexibility is often required. Using target trial emulations comparing immunomodulator treatments for COVID-19, we piloted an adaptive strategy that accommodates warranted mid-course refinements within a prespecified framework. Our preregistered protocol outlined an initial study plan along with predetermined diagnostic thresholds and contingencies. Implementation proceeded through sequential phases, allowing researcher decisions to be guided by prespecified criteria under varying degrees of blinding to results. The adaptive approach led to alterations in the underlying target trial and to the analysis plan used for emulation, strengthening the plausibility of causal assumptions and improving the relevance of findings. During the initial baseline phase, indicated contingencies included sample restrictions, redefining treatments from class-level to product-specific comparisons, a revised propensity score model, and weight truncation. In the subsequent postbaseline phase, diagnostic checks triggered a modified causal contrast, inverse probability of censor weighting to address noncompliance, cause-specific hazard estimation to contextualize competing events, and additional reporting of hazard ratios for progressively truncated follow-up periods. For a secondary study objective, the adaptive framework allowed for some iterative attempts to improve validity while providing a clear stopping point. Similar approaches could lend transparent structure to the process of learning what causal questions the data are equipped to support. Beyond guarding against researcher bias, prespecification of adaptive protocols may promote more robust designs by encouraging investigators to be explicit about their assumptions, strategies for interrogating those assumptions, and specific criteria for determining when and how deviations may be required.<\/jats:p>","DOI":"10.1097\/ede.0000000000001901","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T18:01:59Z","timestamp":1755712919000},"page":"791-801","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Illustrating an Adaptive Prespecification Framework for Observational Research: Target Trial Emulations Comparing Immunomodulator Treatments for COVID-19"],"prefix":"10.1097","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-6796","authenticated-orcid":false,"given":"Andrew R.","family":"Weckstein","sequence":"first","affiliation":[{"name":"Aetion, Inc., New York City, NY"},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5141-1501","authenticated-orcid":false,"given":"Vera","family":"Frajzyngier","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Vititoe","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan","family":"Baglivo","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisha","family":"Beebe","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Govil","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie C.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Perez-Vilar","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna R.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. FDA, Silver Spring, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Lasky","sequence":"additional","affiliation":[{"name":"Office of the Commissioner, U.S. FDA, Silver Spring, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloka","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Office of the Commissioner, U.S. FDA, Silver Spring, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Garry","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolle M.","family":"Gatto","sequence":"additional","affiliation":[{"name":"Aetion, Inc., New York City, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"R1-20260511","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2022.08.012","article-title":"Understanding variation in the results of real-world evidence studies that seem to address the same question.","volume":"151","author":"Wang","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"R2-20260511","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/2042098613477445","article-title":"Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies.","volume":"4","author":"Madigan","year":"2013","journal-title":"Ther Adv Drug Saf"},{"key":"R3-20260511","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/aje\/kwv311","article-title":"Statins and risk of lower limb revision surgery: the influence of differences in study design using electronic health records from the United Kingdom and Denmark.","volume":"184","author":"Lalmohamed","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R4-20260511","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ije\/dyz271","article-title":"Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk.","volume":"49","author":"Chu","year":"2020","journal-title":"Int J Epidemiol"},{"key":"R5-20260511","doi-asserted-by":"crossref","first-page":"111232","DOI":"10.1016\/j.jclinepi.2023.111232","article-title":"Validation and impact of algorithms for identifying variables in observational studies of routinely collected data.","volume":"166","author":"Wang","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"R6-20260511","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jclinepi.2015.05.029","article-title":"Assessment of vibration of effects due to model specification can demonstrate the instability of observational associations.","volume":"68","author":"Patel","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"R7-20260511","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ije\/dyaa164","article-title":"Examining the robustness of observational associations to model, measurement and sampling uncertainty with the vibration of effects framework.","volume":"50","author":"Klau","year":"2021","journal-title":"Int J Epidemiol"},{"key":"R8-20260511","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/aje\/kwab242","article-title":"Addressing posttreatment selection bias in comparative effectiveness research, using real-world data and simulation.","volume":"191","author":"Belviso","year":"2022","journal-title":"Am J Epidemiol"},{"key":"R9-20260511","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/aje\/kwx281","article-title":"When to censor?","volume":"187","author":"Lesko","year":"2018","journal-title":"Am J Epidemiol"},{"key":"R10-20260511","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R11-20260511","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.325.7378.1437","article-title":"Data dredging, bias, or confounding.","volume":"325","author":"Smith","year":"2002","journal-title":"BMJ"},{"key":"R12-20260511","year":"2013"},{"key":"R13-20260511","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials.","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20260511","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them.","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"R15-20260511","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19.","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20260511","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"R17-20260511","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Resp Med"},{"key":"R19-20260511","article-title":"Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial.","author":"Ely","year":"2021","journal-title":"medRxiv [preprint]"},{"key":"R20-20260511","doi-asserted-by":"crossref","first-page":"e222959","DOI":"10.1001\/jamanetworkopen.2022.2959","article-title":"Durability of the single-dose Ad26.COV2.S vaccine in the prevention of COVID-19 infections and hospitalizations in the US before and during the delta variant surge.","volume":"5","author":"Polinski","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R21-20260511","doi-asserted-by":"crossref","first-page":"eabe9403","DOI":"10.1126\/science.abe9403","article-title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.","volume":"370","author":"Gordon","year":"2020","journal-title":"Science"},{"key":"R22-20260511","first-page":"59","article-title":"Risk for newly diagnosed diabetes 30 days after SARS-CoV-2 infection among persons aged 18 years - United States, March 1, 2020-June 28, 2021.","volume":"71","author":"Barrett","year":"2022","journal-title":"MMWR"},{"key":"R23-20260511","article-title":"Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States.","author":"Burn","year":"2021","journal-title":"medRxiv [preprint]"},{"key":"R24-20260511","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/13696998.2021.2002063","article-title":"Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.","volume":"24","author":"Di Fusco","year":"2021","journal-title":"J Med Econ"},{"key":"R25-20260511","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamainternmed.2021.0366","article-title":"Association of SARS-CoV-2 seropositive antibody test with risk of future infection.","volume":"181","author":"Harvey","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R26-20260511","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1503\/cmaj.201686","article-title":"Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study.","volume":"193","author":"Murk","year":"2021","journal-title":"CMAJ"},{"key":"R27-20260511","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pds.5436","article-title":"Categorization of COVID\u201019 severity to determine mortality risk.","volume":"31","author":"Garry","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R28-20260511","doi-asserted-by":"crossref","first-page":"e0248128","DOI":"10.1371\/journal.pone.0248128","article-title":"COVID-19 evidence accelerator: a parallel analysis to describe the use of hydroxychloroquine with or without azithromycin among hospitalized COVID-19 patients.","volume":"16","author":"Stewart","year":"2021","journal-title":"PLoS One"},{"key":"R29-20260511","doi-asserted-by":"crossref","first-page":"ofad339","DOI":"10.1093\/ofid\/ofad339","article-title":"A descriptive cohort study of drug utilization patterns among patients hospitalized with coronavirus disease 2019 in the United States, January 2021\u2013February 2022.","volume":"10","author":"Vititoe","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R31-20260511","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pds.5507","article-title":"HARmonized protocol template to enhance reproducibility of hypothesis evaluating real\u2010world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force.","volume":"32","author":"Wang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R32-20260511","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19.","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R33-20260511","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"R34-20260511","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2021.09.067","article-title":"Real world long-term assessment of the efficacy of tocilizumab in patients with COVID-19: results from a large de-identified multicenter electronic health record dataset in the United States.","volume":"113","author":"Nigo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R35-20260511","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19.","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R36-20260511","doi-asserted-by":"crossref","first-page":"2102532","DOI":"10.1183\/13993003.02532-2021","article-title":"Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support.","volume":"60","author":"Crothers","year":"2022","journal-title":"Eur Respir J"},{"key":"R38-20260511","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"R39-20260511","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"R40-20260511","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/aje\/kwp436","article-title":"Invited commentary: positivity in practice.","volume":"171","author":"Westreich","year":"2010","journal-title":"Am J Epidemiol"},{"key":"R41-20260511","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models.","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R44-20260511","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks.","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"R45-20260511","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","article-title":"Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.","volume":"122","author":"Schuster","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"R46-20260511","doi-asserted-by":"crossref","first-page":"e004580","DOI":"10.1161\/CIRCOUTCOMES.118.004580","article-title":"Importance of considering competing risks in time-to-event analyses application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation.","volume":"11","author":"Abdel-Qadir","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R47-20260511","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research.","volume":"9","author":"Hern\u00e1n","year":"2012","journal-title":"Clin Trials"},{"key":"R48-20260511","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios.","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"key":"R49-20260511","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/aje\/kwz136","article-title":"Diagnosing covariate balance across levels of right-censoring before and after application of inverse-probability-of-censoring weights.","volume":"188","author":"Jackson","year":"2019","journal-title":"Am J Epidemiol"},{"key":"R50-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap methods: another look at the Jackknife.","volume":"7","author":"Efron","year":"1979","journal-title":"Ann Stat"},{"key":"R51-20260511","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"key":"R52-20260511","doi-asserted-by":"crossref","first-page":"ofad426","DOI":"10.1093\/ofid\/ofad426","article-title":"Comparison of tocilizumab vs baricitinib in clinical outcomes among hospitalized patients with COVID-19: experience from a public hospital system in New York City.","volume":"10","author":"Sunny","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R53-20260511","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1073\/pnas.1708274114","article-title":"The preregistration revolution.","volume":"115","author":"Nosek","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R54-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10654-021-00839-0","article-title":"Protecting against researcher bias in secondary data analysis: challenges and potential solutions.","volume":"37","author":"Baldwin","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"R55-20260511","doi-asserted-by":"crossref","first-page":"m4856","DOI":"10.1136\/bmj.m4856","article-title":"STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies.","volume":"372","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"R56-20260511","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cpt.1480","article-title":"A structured preapproval and postapproval comparative study design framework to generate valid and transparent real\u2010world evidence for regulatory decisions.","volume":"106","author":"Gatto","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R57-20260511","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/cpt.2883","article-title":"A structured process to identify fit\u2010for\u2010purpose study design and data to generate valid and transparent real\u2010world evidence for regulatory uses.","volume":"113","author":"Gatto","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"R59-20260511","doi-asserted-by":"crossref","first-page":"e076460","DOI":"10.1136\/bmj-2023-076460","article-title":"Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA sentinel innovation center.","volume":"384","author":"Desai","year":"2024","journal-title":"BMJ"},{"key":"R60-20260511","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1017\/cts.2023.635","article-title":"A causal roadmap for generating high-quality real-world evidence.","volume":"7","author":"Dang","year":"2023","journal-title":"J Clin Transl Sci"},{"key":"R61-20260511","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/EDE.0000000000001585","article-title":"Rejoinder: handgun divestment and risk of suicide.","volume":"34","author":"Swanson","year":"2023","journal-title":"Epidemiology"},{"key":"R62-20260511","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/EDE.0000000000001548","article-title":"Voluntary firearm divestment and suicide risk: real-world importance in the absence of causal identification.","volume":"34","author":"Rudolph","year":"2023","journal-title":"Epidemiology"},{"key":"R63-20260511","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/EDE.0000000000001502","article-title":"When effects cannot be estimated: redefining estimands to understand the effects of naloxone access laws.","volume":"33","author":"Rudolph","year":"2022","journal-title":"Epidemiology"},{"key":"R64-20260511","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/EDE.0000000000000078","article-title":"Causal models and learning from data: integrating causal modeling and statistical estimation.","volume":"25","author":"Petersen","year":"2014","journal-title":"Epidemiology"},{"key":"R65-20260511","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride.","volume":"42","author":"Patorno","year":"2019","journal-title":"Diabetes Care"},{"key":"R66-20260511","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials.","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"key":"R67-20260511","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.2024.2988","article-title":"Data checks before registering study protocols for health care database analyses.","volume":"331","author":"Wang","year":"2024","journal-title":"JAMA"},{"key":"R68-20260511","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1017\/pan.2017.22","article-title":"Using split samples to improve inference on causal effects.","volume":"25","author":"Fafchamps","year":"2017","journal-title":"Polit Anal"},{"key":"R69-20260511","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/EDE.0000000000000020","article-title":"Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studies.","volume":"25","author":"Franklin","year":"2014","journal-title":"Epidemiology"},{"key":"R70-20260511","doi-asserted-by":"crossref","first-page":"e005173","DOI":"10.1161\/CIRCOUTCOMES.118.005173","article-title":"Sequential monitoring of the comparative effectiveness and safety of dabigatran in routine care.","volume":"12","author":"Schneeweiss","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R71-20260511","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/526187a","article-title":"Blind analysis: hide results to seek the truth.","volume":"526","author":"MacCoun","year":"2015","journal-title":"Nature"},{"key":"R72-20260511","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/biom.13808","article-title":"Efficient and robust approaches for analysis of sequential multiple assignment randomized trials: Illustration using the ADAPT-R trial.","volume":"79","author":"Montoya","year":"2023","journal-title":"Biometrics"},{"key":"R73-20260511","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1017\/cts.2023.632","article-title":"An application of the causal roadmap in two safety monitoring case studies: causal inference and outcome prediction using electronic health record data.","volume":"7","author":"Williamson","year":"2023","journal-title":"J Clin Transl Sci"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:00:32Z","timestamp":1778497232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001901","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}